To thwart the rise of non-prescription nootropics, opponents may rally for increased regulation; however, at present, there is insufficient research available to support that non-prescription nootropics pose a danger to public health. Prescription nootropics, such as Ritalin, are already regulated. Further, these drugs have a proven beneficial treatment purpose for intended users.
Even party drugs are going to work: Biohackers are taking recreational drugs like LSD, psilocybin mushrooms, and mescaline in microdoses—about a tenth of what constitutes a typical dose—with the goal of becoming more focused and creative. Many who’ve tried it report positive results, but real research on the practice—and its safety—is a long way off. “Whether microdosing with LSD improves creativity and cognition remains to be determined in an objective experiment using double-blind, placebo-controlled methodology,” Sahakian says.
In fact, many nerve gas agents act similarly to Huperzia serrata by blocking the enzyme that breaks down acetylcholine. But research has shown that in smaller doses, Huperzine A, the extract of Huperzia serrata used in nootropics, would likely offer some protection against damage from nerve agents. That the same substance can act as a nerve agent, protect against nerve agents, and give you crazy dreams, underscores how important it is to stay within the recommended doses.
Systematic reviews and meta-analyses of clinical human research using low doses of certain central nervous system stimulants found enhanced cognition in healthy people. In particular, the classes of stimulants that demonstrate cognition-enhancing effects in humans act as direct agonists or indirect agonists of dopamine receptor D1, adrenoceptor A2, or both types of receptor in the prefrontal cortex. Relatively high doses of stimulants cause cognitive deficits.